FAQ

FAQ published on December 22, 2020
In this activity, Dr. Rampal discusses the many options that can be considered for patients who have anemia with myelofibrosis.
FAQ published on December 16, 2020
Dr. Rampal defines resistant or refractory PV and describes the standard of care for a patient who is hydroxyurea resistant.
FAQ published on December 10, 2020
In this activity, Dr. Raajit Rampal explains what steps to take in establishing the accurate diagnosis of polycythemia vera.
FAQ published on January 20, 2020
Dr. Komrokji discusses treatment management issues when switching from ruxolitinib to fedratinib.
FAQ published on January 20, 2020
Dr. Komrokji discusses whether or not fedratinib can be used in the upfront setting for the treatment of myelofibrosis.
FAQ published on January 20, 2020
Dr. Komrokji discusses how tagraxofusp-erzs is used for the treatment of myelofibrosis and if there is a connection between BPDCN and myelofibrosis.
FAQ published on January 20, 2020
Dr. Komrokji discusses how to determine the best treatment options for each patient using a patient-centered approach.
FAQ published on January 20, 2020
Dr. Komrokji discusses the differences in the adverse event profile between fedratinib and ruxolitinib.
FAQ published on January 20, 2020
Dr. Komrokji discusses the next steps in myelofibrosis research and understanding the biology of the disease.
FAQ published on January 20, 2020
Dr. Komrokji discusses where the JAK inhibitors fit in the treatment of myelofibrosis.
Page 1 of 2
Results 1 - 10 of 13